Abvc Biopharma (ABVC) Non-Current Debt (2014 - 2025)

Abvc Biopharma's (ABVC) quarterly Non-Current Debt came in at $500000.0 in Q3 2025, down 23.08% on a QoQ basis from $650000.0 in Q4 2021.

Abvc Biopharma (ABVC) Non-Current Debt (2014 - 2025) Analysis & Trends

Abvc Biopharma (ABVC) has 7 years of Non-Current Debt data on file, last reported at $500000.0 in Q3 2025.

Quarterly Non-Current Debt changed N/A year-over-year to $500000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $500000.0 (changed N/A YoY) and the FY2021 annual result came in at $650000.0, up 422.51% from the prior year.
Non-Current Debt fell to $500000.0 in Q3 2025, from $650000.0 in the prior quarter.
In the past five years, Non-Current Debt ranged from a high of $650000.0 in Q4 2021 to a low of $104167.0 in Q3 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	139.88 Bn	132.03 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	86.62 Bn	78.62 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	65.28 Bn	60.10 Bn	1.37 Bn	-
4	Moderna	61.39 Bn	56.25 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	42.11 Bn	37.01 Bn	1.53 Bn	882.16 Mn
6	Alnylam Pharmaceuticals	31.37 Bn	28.06 Bn	992.69 Mn	-
7	BioNTech SE	28.76 Bn	10.37 Bn	668.28 Mn	360.97 Mn
8	Insmed	27.46 Bn	26.30 Bn	358.27 Mn	546.77 Mn
9	Royalty Pharma	27.24 Bn	26.41 Bn	-	8.96 Bn
10	Abvc Biopharma	23.97 Mn	23.97 Mn	-	-

Download Data